Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: The treat to target (TTT-Israel) study

Eyal Leibovitz, Dror Harats, Dov Gavish

Research output: Contribution to journalArticlepeer-review


Background: Hyperlipidemia is a major risk factor for coronary heart disease. Reducing low density lipoprotein-cholesterol can significantly reduce the risk of CHD, but many patients fail to reach the target LDL-C goals due to low doses of statins or low compliance. Objectives: To treat high risk patients with atorvastatin in order to reach LDL-C goals (either primary or secondary prevention) of the Israel Atherosclerosis Society. Methods: In this open-label study of 3,276 patients (1,698 of whom were males, 52%), atorvastatin 10 mg was given as a first dose, with follow-up and adjustment of the dose every 6 weeks. While 1,670 patients did not receive prior hypolipidemic treatment, 1,606 were treated with other statins, fibrates or the combination of both. Results: After 6 weeks of treatment, 70% of the patients who did not receive prior hypolipidemic medications and who needed primary prevention reached target LDL-C levels. Interestingly, a similar number of patients who received prior hypolipidemic treatment (other statins, fibrates or both) and who did not reach the LDL-C treatment goals reached the LDL-C goals for primary prevention with atorvastatin. Only 34% of all patients who needed secondary prevention reached the ISA LDL-C target of 100 mg/dl. Atorvastatin proved to be completely safe; only two patients had creatine kinase elevation above 500 U/L, and another six had mild CK elevation (<500 U/L). None of the patients had clinical myopathy, and only one had to be withdrawn from the study. Conclusion: Atorvastatin is a safe and effective drug that enables most patients requiring primary prevention to reach LDL-C goal levels, even with a low dose of 10 mg. Patients in need of secondary prevention usually require higher doses of statins.

Original languageEnglish
Pages (from-to)407-410
Number of pages4
JournalIsrael Medical Association Journal
Issue number6
StatePublished - 2002
Externally publishedYes


  • Atorvastatin
  • Coronary heart disease
  • Low density lipoprotein-cholesterol
  • Statins


Dive into the research topics of 'Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: The treat to target (TTT-Israel) study'. Together they form a unique fingerprint.

Cite this